A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study of YMI024 to assess efficacy in reducing inflammatory markers, safety, and tolerability in adults with stable coronary artery disease and elevated hsCRP

Condition studied

Chronic Kidney Disease, Heart Failure, Coronary Artery disease

Eligibility

Primary endpoint

Change from baseline in log-transformed IL-6

Endpoint detail

Change from baseline in log-transformed IL-6, Change from baseline in log-transformed hsCRP, Responder status (yes/no), defined as hsCRP <2 mg/L, Responder status (yes/no), defined as hsCRP <1 mg/L, Adverse events, and parameters from safety assessments, including vital signs, ECGs, and laboratory assessments (urine and blood) through the end of treatment / study (EOT/EOS)